Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HUMA NASDAQ:MGNX NASDAQ:RZLT NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHUMAHumacyte$2.33-3.7%$2.35$1.15▼$9.79$375.39M1.893.78 million shs1.55 million shsMGNXMacroGenics$1.48-3.9%$1.48$0.99▼$5.77$97.16M1.59836,910 shs381,878 shsRZLTRezolute$5.39-2.7%$4.37$2.22▼$6.19$473.78M1.03669,654 shs664,138 shsUPXIUpexi$7.48+3.3%$8.34$1.90▼$22.57$274.51M-0.581.58 million shs27.52 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHUMAHumacyte+1.26%-3.59%+3.86%+44.05%-70.38%MGNXMacroGenics+1.32%-2.53%+12.41%+22.22%-69.86%RZLTRezolute+3.55%+5.52%+34.14%+101.45%+19.40%UPXIUpexi-0.28%+44.80%-24.50%+214.78%-13.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHUMAHumacyte1.5776 of 5 stars3.51.00.00.01.40.80.6MGNXMacroGenics4.318 of 5 stars3.24.00.04.42.02.50.6RZLTRezolute2.4345 of 5 stars3.61.00.00.02.04.20.0UPXIUpexi1.7585 of 5 stars3.51.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHUMAHumacyte 3.00Buy$11.71402.76% UpsideMGNXMacroGenics 2.40Hold$5.71286.10% UpsideRZLTRezolute 3.14Buy$11.83119.54% UpsideUPXIUpexi 3.00Buy$16.00113.90% UpsideCurrent Analyst Ratings BreakdownLatest MGNX, HUMA, UPXI, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.006/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/20/2025MGNXMacroGenicsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.005/14/2025MGNXMacroGenicsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $3.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/14/2025MGNXMacroGenicsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$6.00 ➝ $5.005/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHUMAHumacyte$1.57M230.21N/AN/A($0.41) per share-5.68MGNXMacroGenics$149.96M0.62N/AN/A$1.85 per share0.80RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/AUPXIUpexi$26M10.91N/AN/A$6.24 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHUMAHumacyte-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)MGNXMacroGenics-$66.97M-$0.89N/AN/AN/A-36.23%-59.84%-23.45%8/5/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%9/29/2025 (Estimated)Latest MGNX, HUMA, UPXI, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025HUMAHumacyte-$0.15N/AN/AN/A$0.94 millionN/A8/5/2025Q2 2025MGNXMacroGenics-$0.59N/AN/AN/A$28.06 millionN/A5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/13/2025Q1 2025MGNXMacroGenics-$0.61-$0.65-$0.04-$0.65$9.59 million$13.19 million5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHUMAHumacyteN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHUMAHumacyte0.363.683.28MGNXMacroGenicsN/A3.283.11RZLTRezoluteN/A8.438.43UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHUMAHumacyte44.71%MGNXMacroGenics96.89%RZLTRezolute82.97%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipHUMAHumacyte5.10%MGNXMacroGenics13.00%RZLTRezolute18.39%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHUMAHumacyte150155.12 million147.21 millionOptionableMGNXMacroGenics43063.09 million54.89 millionOptionableRZLTRezolute4085.52 million69.79 millionOptionableUPXIUpexi13037.92 million25.93 millionOptionableMGNX, HUMA, UPXI, and RZLT HeadlinesRecent News About These CompaniesUpexi Shares Slump After $50M Private Placement Offering ClosesJuly 17 at 7:18 PM | marketwatch.comUpexi call volume above normal and directionally bullishJuly 17 at 7:18 PM | msn.comUpexi Shares Jump After Securing $150 Million in Convertible Notes Backed by SolanaJuly 17 at 7:18 PM | msn.comUpexi Announces Closing of $50 Million Private Placement Equity OfferingJuly 15 at 9:59 PM | manilatimes.netMUpexi Announces Closing of $50 Million Private Placement Equity OfferingJuly 15 at 8:36 AM | globenewswire.comUpexi, Inc. Announces Pricing of $200 Million Concurrent Private ...July 13, 2025 | seekingalpha.comUpexi raises $200M to boost its Solana treasuryJuly 12, 2025 | msn.comUpexi prices $200M private placement of common stock and convertible notesJuly 11, 2025 | msn.comSOL: Nasdaq-Listed Firm Secures $200M in Financing, with Over $150M Tied to Solana Treasury StrategyJuly 11, 2025 | finance.yahoo.comUpexi, Inc. Announces Pricing of $200 Million Concurrent Private Placement of Common Stock and Convertible Notes both Priced above the At-the-Market Price under Nasdaq RulesJuly 11, 2025 | globenewswire.comUpexi (NASDAQ:UPXI) Trading 26.7% Higher - Time to Buy?July 9, 2025 | marketbeat.comUpexi, Inc. (UPXI) Latest Stock News & Headlines - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening Bell | MorningstarJune 27, 2025 | morningstar.comMUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell Platform - NasdaqJune 27, 2025 | nasdaq.comSolana-Focused Upexi to Tokenize Shares; Added 56K SOL to HoldingsJune 26, 2025 | finance.yahoo.comUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening BellJune 26, 2025 | theglobeandmail.comUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell PlatformJune 26, 2025 | quiverquant.comQUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening BellJune 26, 2025 | globenewswire.comSolana Treasury Firm Upexi Falls After Insider Sales FilingJune 25, 2025 | bloomberg.comNews Explorer — Crypto Treasury Chaos: Why Ethereum's SBET and Solana's UPXI Plunged After Routine SEC FilingsJune 25, 2025 | decrypt.coDUpexi stock plunges after filing allows investors to sell sharesJune 24, 2025 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGNX, HUMA, UPXI, and RZLT Company DescriptionsHumacyte NASDAQ:HUMA$2.33 -0.09 (-3.72%) Closing price 04:00 PM EasternExtended Trading$2.39 +0.06 (+2.58%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.MacroGenics NASDAQ:MGNX$1.48 -0.06 (-3.90%) Closing price 04:00 PM EasternExtended Trading$1.48 +0.01 (+0.34%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Rezolute NASDAQ:RZLT$5.39 -0.15 (-2.71%) Closing price 04:00 PM EasternExtended Trading$5.50 +0.11 (+2.04%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Upexi NASDAQ:UPXI$7.48 +0.24 (+3.31%) Closing price 04:00 PM EasternExtended Trading$7.40 -0.08 (-1.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
